![](https://news.europawire.eu/wp-content/uploads/2016/08/SHIRE-LOGO-144x144.jpg)
Integration on track; operating cost synergy expectations increased Pipeline progression continues with FDA approval of XIIDRA for dry eye disease DUBLIN, 04-Aug-2016 — /EuropaWire/ — Shire plc (“Shire”) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended June … Read the full press release